Table 1 Clinical and laboratory findings.
| Measurement | CTLA‐4Ig therapy | ||||
|---|---|---|---|---|---|
| Baseline | 12 months | 15 months | 19 months | 26 months | |
| Tender joint count | 22/28 | 9/28 | 11/28 | 16/28 | 28/28 |
| Swollen joint count | 18/28 | 2/28 | 8/28 | 12/28 | 24/28 |
| C reactive protein (mg/l) | 22.7 | 7.3 | 5.6 | 42.7 | 50.2 |
| DAS‐28 | 6.58 | 4.25 | 4.77 | 6.16 | 7.47 |
| Antinuclear antibodies* | 0 | 1:40 | 1:40 | 0 | 0 |
| Anti‐dsDNA (UI/ml)† | 42 | 13 | 107 | 45 | 30 |
*Antinuclear antibodies are expressed in dilutions. Indirect immunofluorescence on HEp‐2 slides.
†Anti‐dsDNA, anti‐double stranded DNA antibodies (reference range ⩽99 UI/ml).